{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:50:11Z","timestamp":1782276611492,"version":"3.54.5"},"reference-count":69,"publisher":"American Diabetes Association","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":3781,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"DOI":"10.2337\/dc11-s255","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T21:30:32Z","timestamp":1303939832000},"page":"S349-S354","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":10,"title":["Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity"],"prefix":"10.2337","volume":"34","author":[{"given":"Vojtech","family":"Hainer","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Obesity Management Center, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2011,4,22]]},"reference":[{"key":"2022031219020624700_B1"},{"key":"2022031219020624700_B2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajcn\/68.4.899","article-title":"Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary 1\u20133: Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults","volume":"68","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"2022031219020624700_B3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000126822","article-title":"Management of obesity in adults: European clinical practice guidelines","volume":"1","author":"Tsigos","year":"2008","journal-title":"Obes Facts"},{"key":"2022031219020624700_B4","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.2337\/dc08-s265","article-title":"Treatment modalities of obesity: what fits whom?","volume":"31","author":"Hainer","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"2022031219020624700_B6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"2022031219020624700_B8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1467-789X.2008.00463.x","article-title":"Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis","volume":"9","author":"Neovius","year":"2008","journal-title":"Obes Rev"},{"key":"2022031219020624700_B9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.164.13.1395","article-title":"Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis","volume":"164","author":"Norris","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022031219020624700_B10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1467-789X.2009.00567.x","article-title":"Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis","volume":"10","author":"Fabricatore","year":"2009","journal-title":"Obes Rev"},{"key":"2022031219020624700_B11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.ijo.0801059","article-title":"The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction","volume":"23","author":"Hansen","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031219020624700_B12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of sibutramine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"2022031219020624700_B13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1467-789X.2009.00693.x","article-title":"Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis","volume":"11","author":"Johansson","year":"2010","journal-title":"Obes Rev"},{"key":"2022031219020624700_B14","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/dc11-s205","article-title":"Sibutramine on cardiovascular outcome","volume":"34(Suppl. 2)","author":"Scheen","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031219020624700_B16","first-page":"441","article-title":"The use of sibutramine in the management of obesity and related disorders: an update","volume":"5","author":"Tziomalos","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"2022031219020624700_B17","first-page":"817","article-title":"Obesity management: update on orlistat","volume":"3","author":"Drew","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"2022031219020624700_B18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1590\/S0004-27302009000200018","article-title":"The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions","volume":"53","author":"Coutinho","year":"2009","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2022031219020624700_B19","first-page":"875","article-title":"Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo","volume":"7","author":"Samsa","year":"2001","journal-title":"Am J Manag Care"},{"key":"2022031219020624700_B20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.ijo.0802850","article-title":"Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine","volume":"29","author":"Hainer","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"2022031219020624700_B21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2007.00740.x","article-title":"Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success","volume":"10","author":"Elfhag","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2022031219020624700_B22","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","article-title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Astrup","year":"2008","journal-title":"Lancet"},{"key":"2022031219020624700_B23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/ijo.2010.87","article-title":"The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men","volume":"34","author":"Sj\u00f6din","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"2022031219020624700_B24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","article-title":"Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients","volume":"31","author":"Kopelman","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"2022031219020624700_B25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/oby.2009.155","article-title":"Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical)","volume":"18","author":"Kopelman","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","article-title":"Effects of recombinant leptin therapy in a child with congenital leptin deficiency","volume":"341","author":"Farooqi","year":"1999","journal-title":"N Engl J Med"},{"key":"2022031219020624700_B27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.physiol.70.113006.100707","article-title":"Mechanisms of leptin action and leptin resistance","volume":"70","author":"Myers","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"2022031219020624700_B28","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI25977","article-title":"Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight","volume":"115","author":"Rosenbaum","year":"2005","journal-title":"J Clin Invest"},{"key":"2022031219020624700_B29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1677\/JOE-09-0336","article-title":"Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response","volume":"207","author":"Roubert","year":"2010","journal-title":"J Endocrinol"},{"key":"2022031219020624700_B30","doi-asserted-by":"crossref","first-page":"491S","DOI":"10.1002\/j.1550-8528.1995.tb00217.x","article-title":"Clinical studies with dexfenfluramine: from past to future","volume":"3","author":"Guy-Grand","year":"1995","journal-title":"Obes Res"},{"key":"2022031219020624700_B31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.2337\/diacare.20.7.1122","article-title":"Dexfenfluramine in obese Chinese NIDDM patients: a placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors","volume":"20","author":"Chow","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2022031219020624700_B33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"2022031219020624700_B34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031219020624700_B35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","article-title":"Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women","volume":"17","author":"Smith","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B36","first-page":"S52","article-title":"Lorcaserin treatment was associated with improvements in cardiovascular risk factors and weight loss in the BLOOM trial","volume":"17","author":"Anderson","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Shanahan WR; the Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight mnagement","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031219020624700_B38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"2022031219020624700_B39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"2022031219020624700_B40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"2022031219020624700_B41","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B42","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"2022031219020624700_B43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bmcl.2009.12.003","article-title":"Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier","volume":"20","author":"Receveur","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2022031219020624700_B44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden","year":"2000","journal-title":"Obes Res"},{"key":"2022031219020624700_B45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1081\/ERC-200027356","article-title":"Comparison of efficacy of sibutramine or orlistat versus their combination in obese women","volume":"30","author":"Sari","year":"2004","journal-title":"Endocr Res"},{"key":"2022031219020624700_B46","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Arch Intern Med"},{"key":"2022031219020624700_B47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"2022031219020624700_B49","first-page":"19:110\u2013120","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(10)60999-3","article-title":"Is cardiometabolic risk improved by weight-loss drugs?","volume":"376","author":"Astrup","year":"2010","journal-title":"Lancet"},{"key":"2022031219020624700_B51","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B52","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2022031219020624700_B53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/193229680800200525","article-title":"Drugs in the pipeline for the obesity market","volume":"2","author":"Klonoff","year":"2008","journal-title":"J Diabetes Sci Tech"},{"key":"2022031219020624700_B54","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1365-2125.2009.03522.x","article-title":"Obesity treatment: novel peripheral targets","volume":"68","author":"Field","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2022031219020624700_B55","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1331\/JAPhA.2009.09079","article-title":"Efficacy and safety of incretin based therapies: clinical trial data","volume":"49","author":"White","year":"2009","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2022031219020624700_B56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"2022031219020624700_B57","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B59","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B60","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031219020624700_B61","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.2337\/dc08-s269","article-title":"Can gut hormones control appetite and prevent obesity?","volume":"31","author":"Chaudhri","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B62","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219020624700_B63","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2337\/db09-1859","article-title":"PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans","volume":"59","author":"Field","year":"2010","journal-title":"Diabetes"},{"key":"2022031219020624700_B64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1463-1326.2005.00483.x","article-title":"X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance","volume":"7","author":"Toplak","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"2022031219020624700_B65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1463-1326.2005.00481.x","article-title":"Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients","volume":"8","author":"Finer","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"2022031219020624700_B66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"BMJ"},{"key":"2022031219020624700_B67","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"key":"2022031219020624700_B68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMe1004076","article-title":"Drug management of obesity\u2014efficacy versus safety","volume":"363","author":"Astrup","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031219020624700_B69","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1467-789X.2010.00828.x","article-title":"Anti-obesity drugs: to be or not to be?","volume":"11","author":"Dvorak","year":"2010","journal-title":"Obes Rev"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/Supplement_2\/S349\/609086\/s349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/Supplement_2\/S349\/609086\/s349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T20:17:16Z","timestamp":1647116236000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/34\/Supplement_2\/S349\/28350\/Comparative-Efficiency-and-Safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,22]]},"references-count":69,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2011,4,22]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc11-s255","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,22]]}}}